CN1772094A - Hepatitis treating Chinese medicine prepn and its prepn process - Google Patents
Hepatitis treating Chinese medicine prepn and its prepn process Download PDFInfo
- Publication number
- CN1772094A CN1772094A CN 200510021962 CN200510021962A CN1772094A CN 1772094 A CN1772094 A CN 1772094A CN 200510021962 CN200510021962 CN 200510021962 CN 200510021962 A CN200510021962 A CN 200510021962A CN 1772094 A CN1772094 A CN 1772094A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- preparation
- fine powder
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses one kind of hepatitis treating Chinese medicine preparation and its preparation process. The hepatitis treating Chinese medicine preparation is prepared with clover fern, Yinxingcao and garden sorrel as main material as well as schisandra and capillary artemisia. The present invention has reasonable preparation process, has most of its impurity eliminated and effective component concentrated via extraction, separation and purification, and the medicine product has improved moistureproof property, stable and controllable quality and obvious curative effect.
Description
[technical field]
The present invention relates to a kind of Chinese medicine, relate in particular to a kind of Chinese medicine preparation for the treatment of hepatitis and preparation method thereof.
[background technology]
Hepatitis is a kind of common infectious disease, and the crowd of spreading is very wide, all once spreads many countries, race, is one of contemporary main infectious disease.The doctor trained in Western medicine pathology think that it is a kind of inflammation, thus name hepatitis, and it is divided into first type, B-mode, be called viral hepatitis, icterohepatitis according to its clinical manifestation again sometimes, or be called acute hepatitis, chronic hepatitis according to its morbidity emergency degree.At present, the main medicine of western medical treatment hepatitis is antibiotic, antiviral class medicine, and practice shows that therapeutic effect is not fine.In China, in taking usually, doctor trained in Western medicine associated methods treatment hepatitis, obtain remarkable result, generally approved.According to theory of Chinese medical science, hepatitis belongs to temperature, wet disease, thus with soothing the liver, to regulate the flow of vital energy, change strongly fragrant be treatment means, that medicine then mainly adopts is refrigerant, the class medicine is wet in filter.
But the Chinese medicine of existing treatment hepatitis too is limited to classical prescription, nearly all is to add and subtract on the basis of bupleurum root decoction, and is similar, and few people remove to find, study, develop the herbal species and the prescription of other suitable treatment hepatitis.Existing Chinese medicinal formulae is better for the anaphase effect of chronic hepatitis and acute hepatitis, but the previous tretament of acute hepatitis still mainly relies on Western medicine, and is especially not good enough for the hepatitis gravis curative effect, so that treatment cycle is more normal, increased the weight of patient's misery and financial burden.In addition, the dosage form of this class medicine is decoction, powder, pill normally, and the patient takes not too convenient.
[summary of the invention]
Purpose of the present invention provides Chinese patent medicine preparation of the wider treatment hepatitis of a kind of better efficacy, indication and preparation method thereof, and it is more convenient that the dosage form of this medicine allows the patient take.
Technical scheme of the present invention:
A kind of Chinese medicine preparation for the treatment of hepatitis mainly is the medicine of being made by following component:
TIANZICAO 15-50 part, 10～40 parts of Herba Siphonostegiae, 10～40 parts of Radix rumicis acetosaes.
Weight proportion is preferably: 18～30 parts of TIANZICAO, 14～20 parts of Herba Siphonostegiae, 14～30 parts of Radix rumicis acetosaes.
Preferred weight proportion is: 20 parts of TIANZICAO, 15 parts of Herba Siphonostegiae, 15 parts of Radix rumicis acetosaes.
Said medicine also can add 10～30 parts of Fructus Schisandrae Chinensis, 10～30 parts of Herba Artemisiae Scopariaes.
Medicament of the present invention is preferably made capsule, tablet.
The source and the effect thereof of the said Chinese crude drug of technique scheme are as follows:
1. TIANZICAO: function cures mainly and is heat-clearing and toxic substances removing, and inducing diuresis to remove edema is calmed the nerves.Be used for the neurasthenia, dysphoria and insomnia, acute nephritis, acute hepatitis etc.
2. Herba Siphonostegiae: this product is the dry aerial parts of goatweed.Function is a clearing away heat-damp and promoting diuresis, cooling blood and dissolving stasis.Be used for icterohepatitis, lithangiuria, dysuria is had blood in stool etc.
3. Radix rumicis acetosae: this product is the dry root and rhizome of polygonaceae plant Radix rumicis acetosae.Function cures mainly heat clearing away, diuresis, removing heat from blood.
4. Fructus Schisandrae Chinensis: this product is the dry mature fruit of magnoliaceae schisandra.Function is astringent or styptic treatment for spontaneous sweating for convergence, supplementing QI for promoting the production of body fluid, kidney calming.Pharmacological research shows: the mice SGPT that the Fructus Schisandrae Chinensis ethanol extract causes for ATT raises remarkable reduction effect is arranged; Rabbit, rat, mouse liver injury due to the carbon tetrachloride are caused that Glutamate pyruvate transaminase rises has obvious reduction effect; The rat chronic hepatic injury there is obvious protective effect.
5. Herba Artemisiae Scopariae: this product is the dry aerial parts of feverfew Herba Artemisiae Scopariae.Function is clearing away damp-heat, jaundice eliminating subcutaneous ulcer.Be used for the jaundice oliguria, the infectious jaundice hepatitis.Pharmacological research shows: the Herba Artemisiae Scopariae ethanol extraction has secretion of the gallbladder of promotion and Excretion; Hepatic injury there is protective effect.
The preparation method of the above-mentioned Chinese medicine preparation of being made up of TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae comprises the steps:
(1) TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae medical material are made only back cutting, drying;
(2) decoct with water 2～3 times, collecting decoction filters, and filtrate concentrates, and drying under reduced pressure is ground into fine powder;
(3) add filler in fine powder, mixing is granulated, and drying adds lubricant, mixing;
(4) pharmaceutical methods is routinely made capsule or tablet medicine.
The preparation method of the above-mentioned Chinese medicine preparation of being made up of TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae, Fructus Schisandrae Chinensis, Herba Artemisiae Scopariae comprises the steps:
(1) TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae, Fructus Schisandrae Chinensis, Herba Artemisiae Scopariae medical material are made only back cutting, drying;
(2) TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae medical material decoct with water 2～3 times, and collecting decoction filters, concentrated filtrate, and drying under reduced pressure is ground into fine powder A; Fructus Schisandrae Chinensis, Herba Artemisiae Scopariae are adopted ethanol extraction, and extracting solution is concentrated into an amount of adding filler, and drying under reduced pressure is ground into fine powder B;
(3) with fine powder A and fine powder B mixing, add filler, mixing is granulated, and drying adds lubricant, mixing again;
(4) pharmaceutical methods is routinely made capsule or tablet medicine.
The processing of described decoction liquor is adopted and is directly concentrated or process macroporous adsorptive resins adsorbing separation reconcentration technology, is concentrated into relative density 1.25～1.30 (60 ℃).
Described filler is a starch, or dextrin, or calcium sulfate, or wherein one or more of microcrystalline Cellulose, and the filler addition is 5～20% of a fine powder amount.
Described lubricant is micropowder silica gel, or magnesium stearate, or wherein one or more of Pulvis Talci, and the lubricant addition is 0.5～10% of a grain amount.
Described preparation capsule comprises step: add 5～10% filleies in fine powder, mixing is granulated, and drying adds 0.5～10% lubricant, mixing, and capsule charge gets the capsule medicine.
Described preparation tablet comprises step: add the filler of 5-20% in fine powder, mixing is granulated, and drying adds 0.5～10% lubricant, mixing, and compacting is in blocks, and the bag film-coat promptly gets the tablet medicine.
Beneficial effect of the present invention:
Medicine of the present invention is a main Chinese medicinal materials with TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae, presses the Chinese medical theory scientific composition, and indication is wider, and acute viral hepatitis, icterohepatitis, chronic hepatitis and hepatitis gravis are all had significant curative effect.Also in addition Fructus Schisandrae Chinensis, Herba Artemisiae Scopariae, the rising effect is more remarkable unusually to reduce serum glutamic pyruvic transminase.
The present invention extracts Synergistic respectively according to the character of each medical material in the prescription.Medical material significantly reduces invalid element after extracting purification, harmful substance such as persticide residue, heavy metal amount etc. obviously reduce, and dosage is accurate, easy disintegrating, and medicine stability is higher, and bioavailability is better, is easily accepted by the patient.Medicine of the present invention is made tablet, capsule, can satisfy different patients' treatment needs.
Medicine provided by the invention has heat-clearing and toxic substances removing, and the dampness removing jaundice eliminating has the effect that recovers liver function, transaminase lowering.For acute viral hepatitis, icterohepatitis, chronic hepatitis, hepatitis gravis have reasonable therapeutic effect.
[specific embodiment]
Embodiment 1
(1) get it filled 15 parts of material TIANZICAO, 10 parts of Herba Siphonostegiae, 10 parts of Radix rumicis acetosaes, medical material are made back cutting, drying only; (2) decocting that adds 10 times of amounts boils secondary, and each 2 hours, collecting decoction filtered, and it is about 1.28 (60 ℃) that filtrate directly is concentrated into relative density, and 60～80 ℃ of drying under reduced pressure 20 hours are ground into 80 order fine powders; (3) add 5% microcrystalline Cellulose in fine powder, mixing is granulated with 14 mesh sieves, 70 ℃ of dryings 4 hours, and 16 order granulate add 0.5% magnesium stearate, and mixing must hybrid particles; (4) with the tablet machine compacting in flakes, the bag film-coat promptly gets tablet medicine of the present invention with hybrid particles.
Embodiment 2
(1) get it filled 50 parts of material TIANZICAO, 40 parts of Herba Siphonostegiae, 40 parts of Radix rumicis acetosaes, 15 parts of Fructus Schisandrae Chinensis, 15 parts of Herba Artemisiae Scopariaes, medical material are made back cutting, drying only; (2) decocting of TIANZICAO, Herba Siphonostegiae, 10 times of amounts of Radix rumicis acetosae adding boils secondary, each 2 hours, collecting decoction filters, and filtrate is by the macroporous adsorptive resins absorption and purification, closely colourless with 70% ethanol elution to eluent, collect eluent, reclaim ethanol, being concentrated into relative density is 1.30,60～70 ℃ of drying under reduced pressure 18 hours are ground into 100 order fine powder A; Fructus Schisandrae Chinensis, Herba Artemisiae Scopariae were adopted 70% ethanol extraction 3 hours, and it is 1.30 (60 ℃) that extracting solution is concentrated into relative density, added 10% starch, and 70 ℃ of drying under reduced pressure 25 hours are ground into 100 order fine powder B; (3) with fine powder A and fine powder B mixing, add 20% dextrin, mixing is granulated with 14 mesh sieves, 75 ℃ of dryings 5 hours, 16 order granulate add 10% micropowder silica gel, and mixing must hybrid particles; (4) with hybrid particles with the tablet machine compacting in flakes, coating promptly gets tablet medicine of the present invention.
Embodiment 3
(1) get it filled 15 parts of material TIANZICAO, 20 parts of Herba Siphonostegiae, 20 parts of Radix rumicis acetosaes, medical material are made back cutting, drying only; (2) decocting that adds 10 times of amounts boils secondary, each 2 hours, collecting decoction, filter, filtrate is after adsorbent resin absorption, and closely colourless to eluent with 70% ethanol elution, it is about 1.28 (60 ℃) that eluent is concentrated into relative density for 70～80 ℃, 60～70 ℃ of drying under reduced pressure 25 hours are ground into 60 order fine powders; (3) add 10% calcium sulfate in fine powder, mixing is granulated with 14 mesh sieves, 60 ℃ of dryings 4 hours, and 16 order granulate add 2% Pulvis Talci, and mixing must hybrid particles; (4), promptly get capsule medicine of the present invention with the hybrid particles capsule charge.
Below example is further set forth beneficial effect of the present invention by experiment, and these experimental examples have comprised the effect experiment and the pharmacological research of medicine of the present invention.
1. jaundice eliminating reduces the glutamate pyruvate transaminase effect
Irritated stomach tablet of the present invention and capsule 1.25g/kg and subcutaneous injection this product 2.25g/kg in continuous 5 days, once a day, the high serum glutamic pyruvic transminase of the experimental rat hyperbilirubinemia that α-ANIT is caused has significant antagonism; This product effect that adds Fructus Schisandrae Chinensis and Herba Artemisiae Scopariae is more remarkable.
2. diuresis
Oral tablet of the present invention and capsule 0.8g/Kg have diuresis.
3. antiinflammatory action
Subcutaneous injection tablet of the present invention and capsule 0.4g/Kg, the formation that can significantly resist the rat albumen arthritis shows that this product has certain antiinflammatory action.
4. enhance immunity function
Oral tablet of the present invention and capsule 4g/kg, can significantly strengthen Turnover of Mouse Peritoneal Macrophages to the erythrocytic phagocytic activity of chicken, microscopy is found, this product can make the macrophage volume increase, cavity and the huge corpusculum of biting significantly increase, show that this product has the effect that promotes the animal body non-specific immunity, but antagonist formation does not make significant difference.
5. D-galactosamine is caused the protective effect of rat acute hepatic injury
Irritated stomach tablet of the present invention and capsule 1.25g/kg in continuous 5 days, once a day, the experimental rat bran acetone acid transaminase that D-galactosamine is caused, the unusual rising of bran oxalic acid ammonia enzyme have significant antagonism.
6. thioacetamide is caused the protective effect of rat acute hepatic injury
Irritated stomach tablet of the present invention and capsule 1.25g/kg in continuous 5 days, once a day, the experimental rat bran acetone acid transaminase that thioacetamide is caused, the unusual rising of bran oxalic acid ammonia enzyme have significant antagonism, and hepar damnification are had protective effect.
Claims (9)
1. Chinese medicine preparation for the treatment of hepatitis is characterized in that it is to contain the medicament that the following weight proportion raw material is made:
15～50 parts of TIANZICAO, 10～40 parts of Herba Siphonostegiae, 10～40 parts of Radix rumicis acetosaes.
2. the Chinese medicine preparation of treatment hepatitis according to claim 1 is characterized in that the weight proportion of each raw material is: 18～30 parts of TIANZICAO, 14～20 parts of Herba Siphonostegiae, 14～30 parts of Radix rumicis acetosaes.
3. the Chinese medicine preparation of treatment hepatitis according to claim 1 is characterized in that the weight proportion of each raw material is: 20 parts of TIANZICAO, 15 parts of Herba Siphonostegiae, 15 parts of Radix rumicis acetosaes.
4. according to the Chinese medicine preparation of each described treatment hepatitis among the claim 1-3, it is characterized in that said raw material also has 10～30 parts of Fructus Schisandrae Chinensis, 10～30 parts of Herba Artemisiae Scopariaes.
5. according to the Chinese medicine preparation of each described treatment hepatitis among the claim 1-4, it is characterized in that said medicament is capsule or tablet.
6. the preparation method of each described Chinese medicine preparation among the claim 1-3 is characterized in that this preparation method comprises the steps:
(1) TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae medical material are made only back cutting, drying;
(2) medical material decocts with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and drying under reduced pressure is ground into fine powder;
(3) add filler in fine powder, mixing is granulated, and drying adds lubricant, mixing again;
(4) make capsule or tablet medicine according to a conventional method.
7. the preparation method of the described Chinese medicine preparation of claim 4 is characterized in that comprising the steps:
(1) TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae, Fructus Schisandrae Chinensis, Herba Artemisiae Scopariae medical material are made only back cutting, drying;
(2) TIANZICAO, Herba Siphonostegiae, Radix rumicis acetosae medical material decoct with water 2～3 times, and collecting decoction filters, and filtrate concentrates, and drying under reduced pressure is ground into fine powder A; Fructus Schisandrae Chinensis, Herba Artemisiae Scopariae medical material adopt ethanol extraction, and extracting solution is concentrated into an amount of adding filler drying under reduced pressure, is ground into fine powder B;
(3) with fine powder A and fine powder B mixing, add filler, mixing is granulated, and drying adds lubricant, mixing again;
(4) make capsule or tablet medicine according to a conventional method.
8. according to the preparation method of claim 6 or 7 described Chinese medicine preparation, it is characterized in that: the processing of described decoction liquor is adopted and is directly concentrated or process macroporous adsorptive resins adsorbing separation reconcentration technology, is concentrated into relative density 1.25～1.30.
9. according to the preparation method of claim 6 or 7 described Chinese medicine preparation, it is characterized in that: described filler is a starch, or dextrin, or calcium sulfate, or microcrystalline Cellulose wherein one or more, the filler addition of making tablet is 5～20% of a fine powder amount, and the filler addition of making capsule is 5～10% of a fine powder amount; Described lubricant is micropowder silica gel, or magnesium stearate, or Pulvis Talci wherein one or more, the lubricant addition is 0.5～10% of a grain amount.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100219626A CN100402062C (en) | 2005-10-29 | 2005-10-29 | Hepatitis treating Chinese medicine prepn and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100219626A CN100402062C (en) | 2005-10-29 | 2005-10-29 | Hepatitis treating Chinese medicine prepn and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772094A true CN1772094A (en) | 2006-05-17 |
| CN100402062C CN100402062C (en) | 2008-07-16 |
Family
ID=36759345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100219626A Active CN100402062C (en) | 2005-10-29 | 2005-10-29 | Hepatitis treating Chinese medicine prepn and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100402062C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457133C (en) * | 2006-09-29 | 2009-02-04 | 刘跃 | Application of Qiannianai in preparing medicine for treating chronic viral hepatitis B |
| CN102008588A (en) * | 2010-12-16 | 2011-04-13 | 张蕊 | Medicine composition for curing hepatic encephalopathy and hepatitis B |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368120A (en) * | 2001-02-02 | 2002-09-11 | 杨孟君 | Nano medicine 'Jinsuanping' and its preparing process |
-
2005
- 2005-10-29 CN CNB2005100219626A patent/CN100402062C/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457133C (en) * | 2006-09-29 | 2009-02-04 | 刘跃 | Application of Qiannianai in preparing medicine for treating chronic viral hepatitis B |
| CN102008588A (en) * | 2010-12-16 | 2011-04-13 | 张蕊 | Medicine composition for curing hepatic encephalopathy and hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100402062C (en) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1283258C (en) | Medicine for preventing fibrous liver and preparing method thereof | |
| CN1748747A (en) | Chinese medicine compound medicinal preparation for pain killing of channels an dits preparing method | |
| CN100402062C (en) | Hepatitis treating Chinese medicine prepn and its prepn process | |
| CN1709451A (en) | Underleaf pearl formulation for treatig liver-gallbladder diseases and its preparing method | |
| CN1927279A (en) | Chinese medicine composition for treating skin disease | |
| CN101049442A (en) | Preparation of Chinese traditional medicine of clearing away heat and promoting diuresis, promoting blood circulation and activating the channels, and preparation method | |
| CN1298362C (en) | Compound Chinese medicine prepn for treating pulvic infection and its prepn process | |
| CN1785391A (en) | Chinese medicinal composition and its preparation method | |
| CN1954872A (en) | Traditional Chinese medicine composite and its preparation method | |
| CN1943621A (en) | Chinese medicine composition for treating apoplexy and its preparing method | |
| CN1927296A (en) | Chinese medicine composition for treating cervical and lumbar disc disease | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN1098092C (en) | Rheumatism capsule | |
| CN1887316A (en) | Chinese medicine composition and its prepn process and application | |
| CN1911275A (en) | Traditional Chinese medicine composition used for treating brain apoplexia sequela | |
| CN1634260A (en) | Novel method for preparing 'Bazheng Tablet' | |
| CN1672722A (en) | Heart-nourishing and tranquilizing medicine and its prepn process | |
| CN1911360A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation and the like | |
| CN1927350A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1927366A (en) | Traditional Chinese medicine composition for treating chronic enterogastritis | |
| CN1861158A (en) | Dispersing tablets of Liuwei-dihuang extract or its add-substract components, and its prepn. method | |
| CN1911422A (en) | Traditional Chinese medicine composition for treating adenomyosis uteri | |
| CN1236788C (en) | Medicine for curing upper respiratory tract infection and preparation method of its granule preparation | |
| CN1730092A (en) | Chinese traditional medicine compound preparation for treating gynecologic inflammation and process for preparing the same | |
| CN1742798A (en) | Wuhaiyingliu preparation and new preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |